Activity
Mon
Wed
Fri
Sun
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
What is this?
Less
More

Owned by Jimar

This is an educational platform for peptides not medical advice. A community where you can learn and grow together learn with us today.

33 contributions to Peptide EDU
Ready for More: A 4-Day Upper/Lower Plan for Intermediate Lifters
If your beginner full-body routine has stopped moving the numbers, you don't need a fancier program. You need a little more volume, a split that lets you recover, and a simple way to keep adding weight. THE SCIENCE New ACSM guidelines (human evidence, overview of reviews). In March 2026 the American College of Sports Medicine published its first resistance training position stand update in 17 years (Medicine & Science in Sports & Exercise). The core advice: train every major muscle group at least twice a week; for muscle growth, aim for about 10 sets per muscle group per week; for strength, use 2 to 3 sets per exercise with heavy loads around 80% of your 1-rep max. Training to failure, machines vs. free weights, and complicated periodization did not consistently change results for healthy adults. Showing up consistently did. Volume matters, up to a point (human meta-analysis). A Journal of Sports Sciences meta-analysis by Schoenfeld, Ogborn and Krieger found each extra weekly set per muscle was linked to about 0.37% more muscle growth. Groups doing 10+ sets per muscle per week gained about 9.8%, vs. 6.6% for 5 to 9 sets and 5.4% for under 5 sets. Honest caveat: the overall trend was not statistically significant, and removing one study shrank the advantage of 10+ sets. Takeaway: moderate volume is a good target; piling on more is not automatically better. Rest periods (human meta-analysis). A 2024 Bayesian meta-analysis in Frontiers in Sports and Active Living (9 randomized studies) found resting longer than 60 seconds between sets may give a small edge for muscle growth, likely because you keep more weight on the bar. Resting more than 90 seconds added no clear extra benefit for growth. Studies were short (5 to 10 weeks) and mostly in untrained young adults. Why this matters if you're on an incretin drug (human RCT). In a 36-week phase 2 body-composition substudy (Lancet Diabetes & Endocrinology, 2025; 189 adults with type 2 diabetes, DXA scans), retatrutide cut total fat mass by 26.1% at the 8 mg dose studied and 23.2% at the 12 mg dose studied, vs. 4.5% with placebo. Lean mass fell too, by up to about 12.5% in the 8 mg group. The investigators concluded the lean loss was not disproportionate to the weight lost, but it was still real loss. This trial tested the drug, not a lifting program. Retatrutide is investigational and NOT FDA-approved. Resistance training is the best-supported tool you control for holding on to that muscle.
0
0
Elamipretide (SS-31): What Its FDA Approval Really Means
RESEARCH EXPLAINED: SS-31 is one of the few "mitochondria peptides" with an FDA approval, but the approval is narrow, conditional, and built on a mixed set of trials. No big new peptide study or regulatory decision came out in the last 48 hours that we haven't already covered, so today we're breaking down a compound that comes up a lot in mitochondria conversations and hasn't been covered here yet. WHAT IT IS Elamipretide, first developed under the name SS-31, is a small peptide made by Stealth BioTherapeutics. On September 19, 2025, the FDA gave it accelerated approval under the brand name Forzinity. It was the first therapy approved for Barth syndrome and the first FDA-approved drug designed to target mitochondria. (1)(2) Barth syndrome is an ultra-rare genetic disease. The company estimates about 150 people in the U.S. have it, and it occurs in roughly 1 in 1,000,000 male births. (2) The approval covers only one use: improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg. (2)(3) WHAT THEY FOUND TAZPOWER (Barth syndrome). In the randomized, placebo-controlled part of this trial, people took elamipretide for 12 weeks and placebo for 12 weeks in random order. That part did not meet its primary or secondary goals. (4) In the open-label extension, where everyone knew they were on the drug, 8 of 10 participants reached week 168. Six-minute walk distance improved by a combined 96.1 meters by week 168, and fatigue scores and heart measurements also improved. (3)(4) The FDA path. The FDA turned the drug down in May 2025 because it missed a six-minute walk goal. The company resubmitted using knee extensor (thigh) muscle strength, which the FDA treated as an "intermediate" marker likely to predict real benefit, like standing up or walking more easily. (1) MMPOWER-3 (a different disease). In a 24-week Phase 3 trial of 218 adults with primary mitochondrial myopathy, elamipretide at the dose studied in this trial (40 mg daily) did no better than placebo overall. The six-minute walk difference was -3.2 meters, and fatigue scores were also no different. A subgroup with nuclear DNA mutations walked about 25 meters farther than placebo, which the researchers called hypothesis-generating, not proof. (5)
0
0
Sprint Intervals: 1 Hard Minute, Big Mitochondrial Payoff
"No time to train" is the most common reason people skip cardio. One well-run trial suggests a 10-minute session with just 60 seconds of hard work can give your mitochondria a lot of what a 50-minute ride does. THE SCIENCE Sprint intervals vs. steady cardio (human RCT, small). In a 12-week McMaster study (Gillen 2016, PLoS One), 25 sedentary men were split into three groups. One did 10-minute sessions: three 20-second all-out bike sprints with 2 easy minutes between them. One did 45 minutes of steady cycling at about 70% of max heart rate. One did nothing. Both training groups trained 3 times a week. Results: • Fitness (VO2peak) rose 19% in BOTH training groups. • Mitochondrial content (citrate synthase activity) rose 48% with sprints and 27% with steady cardio. • Insulin sensitivity improved about 53% with sprints and 34% with steady cardio. • The sprint group spent about 30 minutes a week training vs. about 150 for steady cardio. Caveats: only 9-10 men per training group, all sedentary, all men. Treat it as strong encouragement, not the final word. NAD+ boosters (human RCT, mixed). NMN is a precursor your body uses to make NAD+, a molecule mitochondria need. In a 6-week double-blind trial (Liao 2021, JISSN), 48 recreational runners (40 men, 8 women) all followed the same supervised training plan and took placebo or NMN at the doses studied in this trial (300, 600 or 1,200 mg/day). The two higher-dose groups improved their ventilatory threshold (the intensity you can hold before breathing gets labored) more than placebo. But VO2max, peak power, body fat and lean mass did not change vs. placebo. The trial did not measure NAD+ levels or mitochondria, the NMN was supplied by a company that sells it, and it has not been independently replicated. Regulatory status: NMN is not a peptide and not an FDA-approved drug. In September 2025, FDA reversed its earlier position and said NMN can be sold as a dietary supplement ingredient (supplements are not reviewed for effectiveness). Neither NMN nor NAD+ is approved to improve performance or body composition. A reminder from our earlier post: MOTS-c, often lumped in here, has no human treatment trials and is prohibited by WADA.
0
0
Safety Group Asks FDA to Block Peptide Compounding
A drug-safety group has formally petitioned the FDA to stop pharmacies from compounding BPC-157, TB-500, MOTS-c and four other peptides, the same week HHS Secretary Kennedy and a U.S. senator pushed for wider access. (1)(2)(3) WHAT IT IS The Partnership for Safe Medicines (PSM) filed a citizen petition with the FDA, announced on October 21. A citizen petition is a formal request anyone can file asking the agency to take, or not take, an action. (1)(2) It targets the seven peptides reviewed at the FDA's July compounding advisory committee meeting: BPC-157, KPV, TB-500, MOTS-c, emideltide (DSIP), Semax and Epitalon. (1) The same week, Secretary Kennedy said on October 20 that the administration wants a state-regulated marketplace for certain unapproved peptides built around 503A compounding pharmacies, and Sen. Roger Marshall wrote to the acting FDA commissioner the next day asking the agency to allow interim compounding with guardrails. (3)(4) WHAT THEY FOUND (WHAT THE PETITION CLAIMS) PSM asks the FDA to block compounding of these peptides by any route and to set aside the July advisory vote as a basis for future rules. (1) It argues the committee was formed in violation of federal advisory committee and ethics laws, saying some newly appointed members have financial ties to the peptide industry. These are PSM's allegations and have not been ruled on. (1) PSM says it bought peptides from four state-licensed compounding pharmacies in Texas and Pennsylvania that shipped to California. It reports three had no known California license and the fourth lacked a non-resident sterile compounding license, and that all came with syringes and injection instructions. (1) For context, the July committee voted 8-6 (one abstention) to recommend adding BPC-157, KPV and TB-500 to the compounding list, also backed MOTS-c, Epitalon and Semax, and voted 6-7 against emideltide. FDA staff had recommended against all seven. (5) HOW IT WORKS Pharmacies can only compound from a bulk ingredient if it meets certain FDA criteria, such as being on the 503A "bulks list." No peptide has been added to that list yet. The advisory votes are recommendations only, and an interim access policy that would let pharmacies compound some peptides was sent to the White House budget office for review on October 14 but has not been issued. (5)
0
0
Smarter Recovery: Deloads, Reps in Reserve and Loading Tendons
Most recovery problems aren't solved by doing less or adding something new. They're solved by dosing your training better, and the research on that is far stronger than anything on "healing peptides." THE SCIENCE Deload weeks (human RCT). In a 2024 PeerJ trial, 39 resistance-trained adults followed a 9-week upper/lower program, taking sets close to failure. One group took a full week off after week 4; the other kept training. Muscle growth (quad thickness) was essentially the same in both groups. But the continuous group gained more strength: squat 1RM rose about 16.4 kg vs. 13.0 kg, and isometric knee extension strength rose about 20 N·m vs. 3 N·m. The authors found no "resensitization" boost from the week off and suggested full breaks be used sparingly when strength is the goal. Note: this tested a complete week off, not a lighter week, and it was a small study in young lifters. You don't need to grind to failure (human evidence review). ACSM's 2026 position stand on resistance training (Medicine & Science in Sports & Exercise) found that training to failure brings no extra gains in strength, size or power, and suggests stopping about 2-3 reps short (2-3 reps in reserve). It recommends at least 10 hard sets per muscle per week for growth, 2-3 sets per exercise for strength, training each muscle at least twice a week, and says simple progression works fine for most adults. Leaving reps in the tank is a built-in recovery tool. Loading, not resting, is the best-studied fix for cranky tendons (human RCT). In a 2009 trial of 39 men with patellar tendinopathy (jumper's knee), heavy slow resistance training was compared with eccentric decline squats and corticosteroid injections over 12 weeks. All three groups improved at first. At 6 months, the injection group had gotten worse, while the heavy slow resistance group kept its gains, had the highest satisfaction, and showed less tendon swelling and more collagen turnover. BPC-157 update (very limited human data). A 2025 paper in Pharmaceuticals reviewed the human evidence and called it very limited: a registered phase I safety trial with unknown status and no published results, small unverified knee-pain reports, and a 2025 IV safety report that included only two people (no side effects reported at the doses studied in that report). There are still no randomized human trials showing it speeds recovery from training or injury. Regulatory status: BPC-157 and TB-500 are not FDA-approved for any use. An FDA advisory committee voted in July 2026 to recommend adding them to the 503A compounding list (against FDA staff advice), but that vote is advisory only; as of the latest legal analyses we reviewed, FDA had not made a final decision. BPC-157 is on WADA's prohibited list.
0
0
1-10 of 33
Jimar Richardson
3
42 points to level up
@jimar-richardson-2983
Free Peptide Coaching

Active 32d ago
Joined Jan 25, 2026